Please ensure Javascript is enabled for purposes of website accessibility

3 Stocks Soaring Higher on These Drug Successes

By Dave Williamson – Feb 19, 2014 at 7:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Three stocks hitting the ceiling today, and the drugs that put them there.

The biotech space had several winners today, and in this segment from Wednesday's Market Checkup, Motley Fool health care analyst David Williamson takes a look at which stocks popped in this space today, and what drove them through the roof.

First up is Chelsea Therapeutics (NASDAQ: CHTP), up a massive 20% on news that its drug Northera was finally approved. Despite the advisory committee's overwhelming support, the market was unsure if this would gain approval, but after delaying its decision from Friday until Tuesday, the FDA gave the thumbs-up.

Next is Furiex (NASDAQ: FURX), which had seen shares skyrocket 130% on the news that its IBS drug had passed its phase 3 trial with flying colors, and has now announced that it is looking for a buyer. The market showed initial enthusiasm on the news that Furiex was for sale, but that sentiment has now cooled slightly, possibly on the realization that finding a buyer may be easier said than done, as the company's drug isn't without its safety issues.

And finally, Eli Lilly (LLY -2.90%) got the win it needed with its critical drug candidate ramucirumab, which showed strong results in a phase 3 trial as a second line non-small cell lung cancer treatment. The market reacted positively with shares climbing about 5%, as the drug achieved statistical significance both in progression-free survival and overall survival rates.

In the video, David tells investors what to expect from these drugs from here, and what he'll be watching for from these companies down the road.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Eli Lilly And Stock Quote
Eli Lilly And
LLY
$360.99 (-2.90%) $-10.80

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.